Urogen Pharma (NASDAQ:URGN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $53.38.
URGN has been the subject of a number of analyst reports. The Goldman Sachs Group reiterated a “neutral” rating and set a $44.00 price target on shares of Urogen Pharma in a research report on Wednesday, July 15th. UBS Group reissued an “outperform” rating on shares of Urogen Pharma in a report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Thursday, October 15th. Oppenheimer set a $60.00 price objective on shares of Urogen Pharma in a report on Thursday. Finally, TD Cowen upped their price objective on shares of Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th.
Check Out Our Latest Analysis on Urogen Pharma
Urogen Pharma Stock Performance
Shares of NASDAQ URGN opened at $24.75 on Friday. Urogen Pharma has a 12-month low of $16.50 and a 12-month high of $50.81. The company has a market cap of $1.21 billion, a PE ratio of -18.75 and a beta of 1.68. The stock has a 50 day simple moving average of $38.78 and a 200-day simple moving average of $31.53.
Urogen Pharma (NASDAQ:URGN – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of $0.11 by ($0.14). The company had revenue of $89.00 million during the quarter, compared to analysts’ expectations of $89.92 million. Sell-side analysts forecast that Urogen Pharma will post -0.36 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, insider Mark Schoenberg sold 871 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $42.92, for a total value of $37,383.32. Following the completion of the transaction, the insider directly owned 59,882 shares in the company, valued at $2,570,135.44. This trade represents a 1.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Chris Degnan sold 2,202 shares of the stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $36.69, for a total transaction of $80,791.38. Following the completion of the transaction, the chief financial officer owned 4,561 shares of the company’s stock, valued at $167,343.09. This trade represents a 32.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 65,269 shares of company stock worth $3,037,646. 4.80% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Urogen Pharma
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sterling Capital Management LLC boosted its stake in Urogen Pharma by 442.1% during the 3rd quarter. Sterling Capital Management LLC now owns 1,339 shares of the company’s stock valued at $54,000 after purchasing an additional 1,092 shares in the last quarter. Persistent Asset Partners Ltd acquired a new position in shares of Urogen Pharma during the 2nd quarter valued at $66,000. Quantbot Technologies LP acquired a new position in shares of Urogen Pharma during the 2nd quarter valued at $78,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Urogen Pharma during the 3rd quarter valued at $101,000. Finally, State of Wyoming raised its stake in shares of Urogen Pharma by 773.4% in the 3rd quarter. State of Wyoming now owns 4,629 shares of the company’s stock worth $188,000 after buying an additional 4,099 shares in the last quarter. Institutional investors own 91.29% of the company’s stock.
About Urogen Pharma
UroGen Pharma Ltd. (NASDAQ: URGN) is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. The company’s therapies are designed to deliver medicines directly to the affected area, with the goal of improving drug exposure while limiting systemic side effects.
UroGen’s primary commercial product is Jelmyto, a mitomycin-based treatment approved in the United States for adults with low-grade upper tract urothelial cancer. Jelmyto uses UroGen’s proprietary RTGel technology, which forms a gel in the urinary tract and enables the sustained local release of mitomycin.
The company has also developed UGN-102, an investigational mitomycin-based reverse thermal gel intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer.
Featured Stories
- Five stocks we like better than Urogen Pharma
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
-inc-logo-1200x675.jpg){kind=logo}
